Literature DB >> 33416497

Mutations in SKI in Shprintzen-Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization.

Ilaria Gori1, Roger George2, Andrew G Purkiss2, Stephanie Strohbuecker3, Rebecca A Randall1, Roksana Ogrodowicz2, Virginie Carmignac4, Laurence Faivre4, Dhira Joshi5, Svend Kjær2, Caroline S Hill1.   

Abstract

Shprintzen-Goldberg syndrome (SGS) is a multisystemic connective tissue disorder, with considerable clinical overlap with Marfan and Loeys-Dietz syndromes. These syndromes have commonly been associated with enhanced TGF-β signaling. In SGS patients, heterozygous point mutations have been mapped to the transcriptional co-repressor SKI, which is a negative regulator of TGF-β signaling that is rapidly degraded upon ligand stimulation. The molecular consequences of these mutations, however, are not understood. Here we use a combination of structural biology, genome editing, and biochemistry to show that SGS mutations in SKI abolish its binding to phosphorylated SMAD2 and SMAD3. This results in stabilization of SKI and consequently attenuation of TGF-β responses, both in knockin cells expressing an SGS mutation and in fibroblasts from SGS patients. Thus, we reveal that SGS is associated with an attenuation of TGF-β-induced transcriptional responses, and not enhancement, which has important implications for other Marfan-related syndromes.
© 2021, Gori et al.

Entities:  

Keywords:  Activin; Marfan syndrome; SKI; SMAD; Shprintzen-Goldberg syndrome; TGF-β; biochemistry; chemical biology; chromosomes; gene expression; human

Mesh:

Substances:

Year:  2021        PMID: 33416497      PMCID: PMC7834018          DOI: 10.7554/eLife.63545

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  85 in total

1.  Structural mechanism of Smad4 recognition by the nuclear oncoprotein Ski: insights on Ski-mediated repression of TGF-beta signaling.

Authors:  Jia Wei Wu; Ariel R Krawitz; Jijie Chai; Wenyu Li; Fangjiu Zhang; Kunxin Luo; Yigong Shi
Journal:  Cell       Date:  2002-11-01       Impact factor: 41.582

2.  A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys.

Authors:  Mayur S Mitra; Karla Lancaster; Adeyemi O Adedeji; Gopinath S Palanisamy; Rutwij A Dave; Fiona Zhong; Matthew S Holdren; Shannon J Turley; Wei-Ching Liang; Yan Wu; Y Gloria Meng; Jean-Michel Vernes; Melissa M Schutten
Journal:  Toxicol Sci       Date:  2020-05-01       Impact factor: 4.849

Review 3.  Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins.

Authors:  Ian B Robertson; Daniel B Rifkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-06-01       Impact factor: 10.005

4.  Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein.

Authors:  S L Stroschein; W Wang; S Zhou; Q Zhou; K Luo
Journal:  Science       Date:  1999-10-22       Impact factor: 47.728

5.  A structural basis for mutational inactivation of the tumour suppressor Smad4.

Authors:  Y Shi; A Hata; R S Lo; J Massagué; N P Pavletich
Journal:  Nature       Date:  1997-07-03       Impact factor: 49.962

Review 6.  TGFβ signalling in context.

Authors:  Joan Massagué
Journal:  Nat Rev Mol Cell Biol       Date:  2012-09-20       Impact factor: 94.444

7.  Induction of heart valve lesions by small-molecule ALK5 inhibitors.

Authors:  Mark J Anderton; Howard R Mellor; Alex Bell; Claire Sadler; Martin Pass; Steve Powell; Samantha J Steele; Ruth R A Roberts; Annabelle Heier
Journal:  Toxicol Pathol       Date:  2011-08-22       Impact factor: 1.902

8.  Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Authors:  Jennifer P Habashi; Daniel P Judge; Tammy M Holm; Ronald D Cohn; Bart L Loeys; Timothy K Cooper; Loretha Myers; Erin C Klein; Guosheng Liu; Carla Calvi; Megan Podowski; Enid R Neptune; Marc K Halushka; Djahida Bedja; Kathleen Gabrielson; Daniel B Rifkin; Luca Carta; Francesco Ramirez; David L Huso; Harry C Dietz
Journal:  Science       Date:  2006-04-07       Impact factor: 47.728

9.  Transforming growth factor beta-independent shuttling of Smad4 between the cytoplasm and nucleus.

Authors:  C E Pierreux; F J Nicolás; C S Hill
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

10.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Authors:  Gareth J Inman; Francisco J Nicolás; James F Callahan; John D Harling; Laramie M Gaster; Alastair D Reith; Nicholas J Laping; Caroline S Hill
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

View more
  3 in total

1.  Smad4 controls signaling robustness and morphogenesis by differentially contributing to the Nodal and BMP pathways.

Authors:  Luca Guglielmi; Claire Heliot; Sunil Kumar; Yuriy Alexandrov; Ilaria Gori; Foteini Papaleonidopoulou; Christopher Barrington; Philip East; Andrew D Economou; Paul M W French; James McGinty; Caroline S Hill
Journal:  Nat Commun       Date:  2021-11-04       Impact factor: 14.919

Review 2.  Insights on the Pathogenesis of Aneurysm through the Study of Hereditary Aortopathies.

Authors:  Tyler J Creamer; Emily E Bramel; Elena Gallo MacFarlane
Journal:  Genes (Basel)       Date:  2021-01-27       Impact factor: 4.096

3.  Mutations in SKI in Shprintzen-Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization.

Authors:  Ilaria Gori; Roger George; Andrew G Purkiss; Stephanie Strohbuecker; Rebecca A Randall; Roksana Ogrodowicz; Virginie Carmignac; Laurence Faivre; Dhira Joshi; Svend Kjær; Caroline S Hill
Journal:  Elife       Date:  2021-01-08       Impact factor: 8.140

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.